PRFX PainReform Ltd
3,374
$0.76
$0.0105
(1.36%)
| Watchers | 3,374 |
| 52-Wk Low | $0.69 |
| 52-Wk High | $26.41 |
| Market Cap | $1.91M |
| Volume | 13,487.00 |
| 52-Wk High | $26.41 |
| 52-Wk Low | $0.69 |
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing ConditionsBenzinga • about 1 month ago
PainReform reveals superior IVR rates of PRF-110 vs. competitors in post-surgical pain management. Findings showcase PRF-110's extended analgesic effect potential, reducing opiate dependency.
read...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Remains on track to announce top-line data by mid-2024TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...
PainReform files to sell shares...
Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid-2024 TEL AVIV, Israel, March 01, 2024 (GLOBE...
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ('PainReform' or the 'Company'), a clinical-stage specialty pharmaceutical company focused on the reformulation...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreadingTEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...